{
    "root": "f4eb6157-0321-467a-a06b-69c2970eda71",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "lurasidone hydrochloride"
    },
    "value": "20250306",
    "ingredients": [
        {
            "name": "LURASIDONE HYDROCHLORIDE",
            "code": "O0P4I5851I"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "lurasidone hydrochloride indicated : \u2022 treatment adult adolescent patients ( 13 17 years ) schizophrenia [ ( 14.1 ) ] . \u2022 monotherapy treatment adult pediatric patients ( 10 17 years ) major depressive episode associated bipolar disorder ( indication ) [ ( 14.2 ) ] . \u2022 adjunctive treatment lithium valproate adult patients major depressive episode associated bipolar disorder ( indication ) [ ( 14.2 ) ] .",
    "contraindications": "lurasidone hydrochloride taken food ( least 350 calories ) . food substantially increases absorption lurasidone hydrochloride ( 2.3 , 12.3 ) . indication starting dose recommended dose schizophrenia \u2013 adults ( 2.1 ) 40 mg per day 40 mg 160 mg per day schizophrenia \u2013 adolescents ( 13 17 years ) ( 2.1 ) 40 mg per day 40 mg 80 mg per day indication\u2013 adults ( 2.2 ) 20 mg per day 20 mg 120 mg per day indication\u2013 pediatric patients ( 10 17 years ) ( 2.2 ) 20 mg per day 20 mg 80 mg per day \u2022 moderate severe renal impairment : recommended starting dose 20 mg per day , maximum recommended dose 80 mg per day ( 2.4 , 8.6 ) . \u2022 moderate severe hepatic impairment : recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day moderate hepatic impairment 40 mg per day severe hepatic impairment ( 2.5 , 8.7 ) . \u2022 concomitant moderate cyp3a4 inhibitor ( e.g . , diltiazem ) : lurasidone hydrochloride dose reduced half original dose level . recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day ( 2.6 , 7.1 ) . \u2022 concomitant moderate cyp3a4 inducer : may necessary increase dose lurasidone hydrochloride ( 2.6 , 7.1 ) .",
    "warningsAndPrecautions": "lurasidone hydrochloride tablets white off-white , round ( 20 mg 40 mg ) , white off-white , capsule ( 60 mg ) , light yellow , oval ( 80 mg ) white off-white , oval ( 120 mg ) identified strength-specific one-sided debossing , \u201c f3 \u201d ( 20 mg ) , \u201c f4 \u201d ( 40 mg ) , \u201c f5 \u201d ( 60 mg ) , \u201c f6 \u201d ( 80 mg ) \u201c f7 \u201d ( 120 mg ) . tablets supplied following strengths package configurations ( table 39 ) . table 39 : package configuration lurasidone hydrochloride tablets tablet strength package configuration ndc code 20 mg bottle 30 33342-419-07 bottle 90 33342-419-10 40 mg bottles 30 33342-420-07 bottles 90 33342-420-10 60 mg bottles 30 33342-421-07 bottles 90 33342-421-10 80 mg bottles 30 33342-422-07 bottles 90 33342-422-10 120 mg bottles 30 33342-423-07 bottles 90 33342-423-10 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022 known hypersensitivity lurasidone hcl components formulation . angioedema observed lurasidone [ ( 6.1 ) ] . \u2022 strong cyp3a4 inhibitors ( e.g . , ketoconazole , clarithromycin , ritonavir , voriconazole , mibefradil , etc . ) [ ( 7.1 ) ] . \u2022 strong cyp3a4 inducers ( e.g . , rifampin , avasimibe , st. john \u2019 wort , phenytoin , carbamazepine , etc . ) [ ( 7.1 ) ] .",
    "indications_original": "Lurasidone hydrochloride is indicated for:\u00a0\n                  \u2022\u00a0Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.1)].\u00a0\n                      \u2022\u00a0Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (other indication) [see Clinical Studies (14.2)].\u00a0\n                      \u2022\u00a0Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (other indication) [see Clinical Studies (14.2)].",
    "contraindications_original": "Lurasidone hydrochloride should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride ( 2.3 , 12.3 ). Indication Starting Dose Recommended Dose Schizophrenia \u2013 adults ( 2.1 ) 40 mg per day 40 mg to 160 mg per day Schizophrenia \u2013 adolescents (13 to 17 years) ( 2.1 ) 40 mg per day 40 mg to 80 mg per day other indication\u2013 adults ( 2.2 ) 20 mg per day 20 mg to 120 mg per day other indication\u2013 pediatric patients (10 to 17 years) ( 2.2 ) 20 mg per day 20 mg to 80 mg per day \u2022\u00a0Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day ( 2.4 , 8.6 ). \u2022 Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment ( 2.5 , 8.7 ). \u2022 Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem): Lurasidone hydrochloride dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day ( 2.6 , 7.1 ). \u2022\u00a0Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride ( 2.6 , 7.1 ).",
    "warningsAndPrecautions_original": "Lurasidone hydrochloride tablets are white to off-white, round (20 mg or 40 mg), white to off-white, capsule (60 mg), light yellow, oval (80 mg) or white to off-white, oval (120 mg) and identified with strength-specific one-sided debossing, \u201cF3\u201d (20 mg), \u201cF4\u201d (40 mg), \u201cF5\u201d (60 mg), \u201cF6\u201d (80 mg)\u00a0 or \u201cF7\u201d (120 mg). Tablets are supplied in the following strengths and package configurations (Table 39).\n                  \n                     Table 39: Package Configuration for Lurasidone Hydrochloride Tablets\n                  \n                  \n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n                  \n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                           \u00a0Tablet Strength \n                              \u00a0\n                           \u00a0Package Configuration \n                              \u00a0\n                           \u00a0NDC Code \n                              \u00a0\n                        \n                        \n                           \u00a020 mg \u00a0\n                           \u00a0Bottle of 30 \u00a0\n                           \u00a033342-419-07\u00a0\n                        \n                        \n                           \u00a0Bottle of 90 \u00a0\n                           \u00a033342-419-10\u00a0\n                        \n                        \n                           \u00a040 mg \u00a0\n                           \u00a0Bottles of 30 \u00a0\n                           \u00a033342-420-07\u00a0\n                        \n                        \n                           \u00a0Bottles of 90 \u00a0\n                           \u00a033342-420-10\u00a0\n                        \n                        \n                           \u00a060 mg \u00a0\n                           \u00a0Bottles of 30 \u00a0\n                           \u00a033342-421-07\u00a0\n                        \n                        \n                           \u00a0Bottles of 90 \u00a0\n                           \u00a033342-421-10\u00a0\n                        \n                        \n                           \u00a080 mg \u00a0\n                           \u00a0Bottles of 30 \u00a0\n                           \u00a033342-422-07\u00a0\n                        \n                        \n                           \u00a0Bottles of 90 \u00a0\n                           \u00a033342-422-10\u00a0\n                        \n                        \n                           \u00a0120 mg \u00a0\n                           \u00a0Bottles of 30 \u00a0\n                           \u00a033342-423-07\u00a0\n                        \n                        \n                           \u00a0Bottles of 90 \u00a0\n                           \u00a033342-423-10\u00a0\n                        \n                     \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022\u00a0Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)]. \n                      \u2022\u00a0Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].\n                      \u2022\u00a0Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John\u2019s wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)]."
}